Celebrating Excellence at the Asia-Pacific Biopharma Excellence Awards 2025

Singapore, March 2025 – The Asia-Pacific Biopharma Excellence Awards (ABEA) 2025 celebrated the visionaries shaping the future of biopharma, recognizing outstanding achievements in bioprocessing, logistics and supply chain management, ADC development, and clinical trials. This year’s awards honored the exceptional experts, organizations, and groundbreaking technologies that have driven innovation and excellence over the past year.

WuXi Biologics Leads with Five Wins

WuXi Biologics emerged as the big winner, securing five awards, including

• Best Contract Development and Manufacturing Organization Award
• Best New Modalities Manufacturing Company
• Best Bioprocessing Supplier Award: Cell Line Development & Characterization
• Best Aseptic Fill-Finish & Packaging CMO of the Year
• Best Aseptic Fill-Finish & Packaging Supplier Award: Drug Delivery Systems

Their commitment to advancing bioprocessing and biomanufacturing excellence continues to set industry benchmarks.

Spotlight on Emerging CDMOs: 3 Award Winners Have Been Recognised

The Emerging CDMO of the Year category saw three standout winners, including Locus Cell, BiBo Pharma Engineering, Aurigene Pharmaceutical Services, highlighting the rise of innovative players in contract development and manufacturing across Asia-Pacific.

13 New Categories Added to Recognise ADC Excellence

With the growing prominence of Antibody-Drug Conjugates (ADCs) in biopharma, 13 new award categories were introduced this year. Here are the winners:

🏆 Best ADC CDMO in Asia – WuXi XDC
‍🏆 Best ADC CDMO in China – WuXi XDC
‍🏆 Best ADC CDMO in South Korea – Samsung Biologics
‍🏆 Best ADC CDMO in Taiwan – EirGenix
‍🏆 Best ADC CRO in Asia – WuXi XDC
‍🏆 Best ADC Developer in China – InnoLake Biopharm
‍🏆 Best ADC Developer in Southeast Asia – Baiya Phytopharm
‍🏆 Best ADC Developer in Taiwan – Honeybear Biosciences
‍🏆 Best ADC Platform Technology – WuXi XDC
‍🏆 Most Promising ADC Clinical Candidate in Asia – Hummingbird Bioscience
‍🏆 Most Promising ADC Clinical Candidate in China – GeneQuantum Healthcare
‍🏆 Most Promising ADC Clinical Candidate in Japan – Astellas
‍🏆 Most Promising ADC Clinical Candidate in Taiwan – OBI Pharma

ABEA 2025 winners were selected through an industry-led, transparent process. Finalists were shortlisted based on impact, innovation, and leadership, with winners determined by votes from the biopharma community.

Download our full winners list here: link‍

About IMAPAC

IMAPAC is a leading Life Science Marketing Partner specialising in business networking, biopharma data insights, and digital engagement solutions. Dedicated to fostering innovation and strategic collaboration, IMAPAC supports the global biopharma ecosystem through knowledge-sharing and industry recognition.

Media Contact
Litsa Francis
Marketing Strategist, IMAPAC
litsa@imapac.com